Author

E. Beal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Aboukameel· 2 shared A. S. Azmi· 2 shared H. Y. Khan· 2 shared M. H. Uddin· 2 shared S. Kim· 2 shared A. F. Shields· 1 shared A. Ibrahim· 1 shared A. Thangasamy· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Aboukameel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis

S. F. Bannoura, A. Aboukameel, H. Y. Khan, M. H. Uddin, H. Jang, E. Beal, A. Thangasamy, S. Kim, K.-U. Wagner, R. Mohammad, M. N. Al Hallak, B. Pasche, A. S. Azmi

This study identifies RCC1 as a novel therapeutic target in PDAC, showing its role in tumor progression and drug resistance through the c-Myc-RCC1-Ran axis.

bioRxiv · Dec 18, 2023 · PreprintCancer Biology

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

H. Y. Khan, M. Nagasaka, A. Aboukameel, O. Alkhalili, M. H. Uddin, S. Bannoura, Y. Mzannar, A. Ibrahim, E. Beal, M. Tobon, S. Kim, R. Beydoun, E. Baloglu, W. Senapedis, B. Elrayes, , A. S. Azmi

This study shows that combining KRASG12C inhibitors with PAK4 inhibitor KPT9274 enhances antitumor activity and survival in preclinical models of KRASG12C mutant pancreatic and lung cancers.

bioRxiv · Mar 27, 2023Cancer Biology